To determine the role of eplerenone as a treatment modality for chronic central serous chorioretinopathy – A case series

This case series was conducted to assess the role of eplerenone in the treatment of chronic Central serous chorioretinopathy (CSCR). This retrospective case series included patients with chronic CSCR who received oral eplerenone. Best-corrected visual acuity was recorded and converted to logMAR units. Spectral-domain optical coherence tomography was used to assess subretinal fluid (SRF) height and central macular thickness (CMT) at baseline and at 30 and 90 days during follow-up. Eight eyes from eight patients were included. All patients were male. Mean logMAR visual acuity improved from 0.3875 at baseline to 0.125 at 90 days. Mean CMT decreased from 451.38 mm to 293.38 mm, and mean SRF height decreased from 201.62 mm to 77.25 mm. A progressive reduction in SRF height and CMT was observed over the follow-up period, along with improvements in visual acuity. Oral eplerenone appears to be a beneficial therapeutic option in selected cases of chronic CSCR, particularly among young patients with central vision loss. Eplerenone may be considered for patients experiencing stress related to vision loss that disrupts their daily work activities.